Related Experiment Video

Updated: Dec 22, 2025

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.3K

Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer

Di Zhao1,2, Li Cai1, Xin Lu1,3

  • 1Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer Discovery
|May 10, 2020
PubMed

Insights

Genetic inactivation of the PTEN gene in prostate cancer necessitates CHD1. Deleting CHD1 in PTEN-deficient tumors delays progression and reshapes the tumor microenvironment, suggesting combined IL6 and immune checkpoint inhibitor therapy.

Area of Science:

  • Oncology
  • Cancer Genetics
  • Immunology

Background:

  • PTEN gene inactivation is prevalent in prostate cancer, often leading to poor prognosis.
  • CHD1 has been identified as essential for the survival of PTEN-deficient cancer cells.

Purpose of the Study:

  • To provide in vivo genetic evidence for CHD1's essential role in PTEN-deficient prostate cancer.
  • To elucidate the mechanistic understanding of CHD1's function in this context.

Main Methods:

  • Utilized Pten and Pten/Smad4 genetically engineered mouse models.
  • Performed prostate-specific deletion of Chd1.
  • Analyzed tumor microenvironment (TME) changes, including immune cell populations and gene expression.

Main Results:

  • Prostate-specific Chd1 deletion significantly delayed tumor progression and extended survival in mouse models.
  • Chd1 deletion led to substantial TME remodeling, characterized by decreased myeloid-derived suppressor cells (MDSCs) and increased CD8+ T cells.
  • Identified IL6 as a key transcriptional target of CHD1, crucial for MDSC recruitment.

Conclusions:

  • CHD1 plays a critical role in regulating the immunosuppressive TME of PTEN-deficient prostate cancer through the CHD1/IL6 axis.
  • Targeting IL6 in combination with immune checkpoint inhibitors (ICIs) shows promise for treating PTEN-deficient prostate cancer due to improved anti-tumor responses.

More Related Videos

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.9K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.1K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.5K
Chromatin Modification in iPS Cells01:32

Chromatin Modification in iPS Cells

Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
2.1K